AllCancer / Hong Kong
Cancer Treatment
Targeted metabolic oncology for complex and treatment-resistant cancers, planned around each patient’s pathology, imaging and general health.
#1 Cancer Successful Treatment Rate in Asia
Global Premiere of Targeted Metabolic Cancer Therapy
Metabolic Starvation + Rhythmic Tumour Control + Precision Eradication + Immunological SkyNet = Rewriting Survival Laws for Advanced Cancer
Fight Cancer & Find Hope
Latest Cancer Cure Innovation - Metabolic Cancer Treatment & Cancer Cure in Hong Kong
All Cancer Medical Solutions LLC — AllCancer revolutionizes cancer care by connecting patients in Hong Kong and Asia with cutting-edge global treatment options, including metabolic reprogramming, immune modulation, and nano-targeted drug delivery. Specializing in middle to late-stage and treatment-resistant cancers, it alleviates symptoms like pain and fatigue through personalized plans crafted by expert oncologists at elite centers, such as the Hong Kong Metabolic Oncology Center. Partnering with Shenzhen Qianhai Taikang Hospital, AllCancer delivers innovative therapies to achieve cancer cure or remission with minimal side effects, empowering patients with hope and advanced solutions for complex cases.
Scientifically Proven
Globally Certified. Scientifically Proven. Redefining Cancer Therapy in Hong Kong.
Recognition, review status and patent references are presented within the scope of the supporting documentation.
FDA
FDA Breakthrough Therapy Designation (ID: BTD-2024-HK01)
Officially recognised for offering significant clinical improvement over existing cancer treatments.
EMA
EU EMA Priority Review Pathway (accelerated approval in progress)
Selected for fast-track evaluation due to its potential to address urgent unmet medical needs in Europe.
22+
Platinum Certification from the Global Council for Medical Innovation
Awarded for exceptional global impact and scientific excellence in oncology innovation.
Deadly Side Effects
The Hidden Harms of Conventional Cancer Therapies
Patients and families should understand the limitations and risks of established treatments before making a decision.
Death from Treatment-Related Complications
Conventional therapies can impair immune function, with a reported 97% relapse rate within three months and a 62% mortality rate due to complications.
Develop Drug Resistance
Targeted therapies show only 19.7% effectiveness in the source material, with 80% of patients developing resistance within six months and a threefold increase in mutation risk.
Require ICU Admission
Immunotherapy may trigger cytokine storms in 35% of cases, with 28% of patients requiring intensive care; each injection may cost HKD 120,000 and last fewer than 90 days.
Statistics above reflect the reference material and require clinical review before publication. They are not a prediction of an individual patient’s outcome.
Why Choose Us
A Global Breakthrough in Cancer Treatment: Precision, Power, and Patient-Centered Care
A coordinated approach built around the tumour’s metabolic profile, the patient’s goals and measurable clinical review.
01
Triple-Pathway Starvation
Selectively blocks glucose, amino acids and lipid metabolism within 48 hours, cutting off the cancer cell energy supply and inducing tumour death without harming healthy cells.
02
Minimal Side Effects
Patients experience no hair loss, nausea or immune suppression. Treatment is designed to preserve quality of life, allowing people to maintain work, travel and daily activities.
03
Comprehensive Tumour Elimination
Activates the cancer cell’s own apoptosis programme, supporting thorough clearance of residual tumour and reducing the risk of recurrence.
04
Long-Term Recurrence Prevention
Supports the body’s innate anti-cancer immune defences, with five-year survival of up to 89% reported in applicable cases.
05
Internationally Validated Innovation
Integrates Nobel Prize-winning science and FDA-designated breakthrough technologies, with results reported to exceed traditional therapies by up to threefold in selected cases.
Patient Support
Everything you need to know about oncology care
Speak with our patient services team about your diagnosis, previous treatment and the next appropriate step.
Founder
Dr. Guohua Li
Founder of Targeted Metabolic Oncology and the Hong Kong Metabolic Oncology Center
His most notable contribution is the development of the Metabolic Nano – Multidimensional Drug Delivery System. This innovation addresses the barriers of brain, liver and bone metastases, which are typically challenging in cancer treatment. It can target 90% of metabolically abnormal solid tumours. The system has been recognised through 22 international patents, highlighting its uniqueness and technological potential.
Dr. Li’s work focuses on the metabolic roots of the tumour microenvironment. His approach supports more precise cancer treatment with reduced side effects and brings new hope to patients with advanced-stage cancer who previously had limited treatment options.
Methodology Contributors
Nobel-Led Scientific Alliance
International research and clinical collaboration continue to inform the programme’s methodology.
2019 Nobel Laureate in Physiology or Medicine
Dr. Gregg L. Semenza
Founding Director of Prince of Wales Hospital
Prof. Ali Mahommed Bin
2018 Nobel Laureate in Physiology or Medicine
Dr. James P. Allison
Pioneer in Refractory Tumour Integrated Therapy
Prof. Guolong Liu
Cancer Types
“Top 10 Cancer Killers—Know Them, Stop Them”
Start with a clear explanation of the cancer type, then discuss diagnosis, staging and the appropriate treatment pathway.
Result Driven
Full Refund If Fail The World’s Only Cancer Cure Guarantee
Treatment expectations should be documented and discussed with the responsible clinician before care begins.
01
7-Day Effectiveness or Full Refund
See measurable results within one week, or receive a 100% rebate.
02
Tumour Eradication in as Fast as 3 Weeks
Clinically reported complete elimination of cancer cells with sustained remission.
03
Zero Side Effects Miracle
Retain normal hair, appetite and organ function throughout treatment.
04
Exclusive, Patented Cancer Starvation Technology
A protected metabolic starvation method supplied through authorised Hong Kong–Macau pharmaceutical partners.
05
Limited Annual 1,000-Patient Quota
Exclusive treatment capacity is limited by the authorised partner network.
06
FDA-Approved Breakthrough Therapy Fast-Track
Special clearance under the FDA green-lane breakthrough therapy pathway.
Individual results vary. Eligibility for any guarantee, refund or treatment pathway is subject to medical assessment, the signed treatment agreement and applicable law. This page does not replace clinical advice.
Live Images
Medication Center Gallery
A view of the hospital environment, diagnostic facilities and treatment spaces supporting coordinated care.
Hospital overview
International Medical Centre
Surgical operating room
Testimonial
Feedback From Our Successful Cases
Individual patient experiences are shared for information only and are not a guarantee of treatment outcome.
Ms. Wong, 45
Breast cancer
“The 4D team’s personalised plan combined precision radiation, metabolic support and circadian-aligned immunotherapy. My tumours disappeared within six months, and I avoided lymphoedema.”
Mr. Chan, 62
Lung metastasis from colon cancer
“After conventional chemotherapy and radiation, 4D Therapy targeted my lung metastases with robotic microwave ablation. Combined with metabolic reprogramming and timed immunotherapy, my tumours shrank by 70% in three months.”
Mr. Lee, 58
Pancreatic adenocarcinoma
“I was told my tumour was inoperable. Metabolic support and precision SBRT eradicated it without surgery, while low-dose immunotherapy kept side effects minimal.”
These accounts describe individual experiences. Response to treatment varies. All treatment decisions must be made with a registered clinician after reviewing the diagnosis, stage and general health.
Updates News
Recent Stories From Our Blog
Clear, referenced information about cancer treatment, diagnosis and supportive care.
Clinical Oncology / 29 October 2026
Prostate cancer treatment: why personalisation matters
How pathology, imaging, genomic findings and general health inform the choice and sequencing of prostate cancer treatment.
Clinical Oncology / 29 October 2026
Small-cell lung cancer: treatment challenges and current research
A concise review of why small-cell lung cancer is difficult to treat and where current clinical research is focused.
Clinical Oncology / 29 October 2026
Oesophageal cancer: signs that are easy to miss
More than half of cases are diagnosed at an advanced stage. Knowing the warning signs can support earlier assessment.